This company was transferred to the archive: financial data is no longer updated!

Microsoft Excel LibreOffice Calc

Celgene Corp. (NASDAQ:CELG)


Analysis of Liquidity Ratios
Quarterly Data

Beginner level


Liquidity Ratios (Summary)

Celgene Corp., liquidity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Current ratio 2.89 3.44 2.78 2.23 2.13 1.52 2.53 4.99 3.65 4.05 4.42 3.67 3.61 4.61 4.57 4.77 3.23 3.34 4.61 4.60 6.32 5.44 2.86
Quick ratio 2.65 3.20 2.53 2.00 1.76 1.22 2.16 4.67 3.35 3.66 3.98 3.24 3.19 3.99 3.89 4.05 2.79 2.96 4.05 4.13 5.67 4.92 2.55
Cash ratio 2.18 2.53 1.94 1.49 1.19 0.76 1.52 4.03 2.90 3.13 3.37 2.69 2.59 3.22 3.11 3.33 2.39 2.53 3.49 3.57 4.91 4.17 2.11

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-30), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-07), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-10), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-05-03), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-07-28), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-20), 10-Q (filing date: 2014-10-28), 10-Q (filing date: 2014-07-29), 10-Q (filing date: 2014-04-29).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Celgene Corp.’s current ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Celgene Corp.’s quick ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Celgene Corp.’s cash ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level.

Current Ratio

Celgene Corp., current ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Current assets 14,454  12,683  10,981  9,067  7,827  6,853  7,872  14,892  14,783  13,136  11,617  10,868  9,576  9,169  8,386  9,401  10,152  9,884  9,665  9,713  8,836  8,107  6,942 
Current liabilities 5,009  3,685  3,955  4,057  3,683  4,502  3,115  2,987  4,049  3,240  2,629  2,959  2,649  1,987  1,834  1,969  3,144  2,960  2,097  2,112  1,398  1,492  2,425 
Liquidity Ratio
Current ratio1 2.89 3.44 2.78 2.23 2.13 1.52 2.53 4.99 3.65 4.05 4.42 3.67 3.61 4.61 4.57 4.77 3.23 3.34 4.61 4.60 6.32 5.44 2.86
Benchmarks
Current Ratio, Competitors2
Abbott Laboratories 1.54 1.68 1.58 1.62 1.42 1.58 1.66 2.26 2.69 2.94 2.91 4.02 1.56 1.50 1.48 1.54 1.82 2.30 2.17
AbbVie Inc. 1.15 0.89 1.04 0.98 1.20 0.80 1.20 1.28 1.45 1.38 1.76 1.65 1.79 1.81 1.56 1.50 2.03 1.50 1.39
Allergan PLC 1.00 1.03 0.71 1.13 0.92 1.00 1.10 1.16 1.18 1.21 1.32 2.27 3.95 0.99 0.99 1.03 2.05 1.37 1.44
Amgen Inc. 2.89 2.89 2.77 2.79 3.08 3.39 3.88 5.49 6.07 6.20 4.41 4.11 4.35 3.97 4.95 4.44 5.42 5.48 5.53
Biogen Inc. 1.91 2.46 2.84 2.32 2.75 2.36 3.23 2.34 2.19 2.10 2.29 2.55 3.24 2.96 2.59 2.60 3.52 2.20 2.70
Bristol-Myers Squibb Co. 3.83 3.88 1.93 1.61 1.53 1.40 1.52 1.55 1.59 1.59 1.60 1.55 1.47 1.56 1.48 1.30 1.81 1.76 1.94
Eli Lilly & Co. 1.17 1.13 1.12 1.73 1.91 1.40 1.41 1.32 1.38 1.39 1.24 1.37 1.62 1.54 1.60 1.53 1.51 1.50 1.41
Gilead Sciences Inc. 2.96 3.76 3.62 3.38 3.45 3.00 2.84 2.74 3.68 3.37 2.59 2.22 1.93 1.76 1.77 2.50 2.77 2.03 2.70
Illumina Inc. 6.82 6.79 3.66 2.49 2.46 2.74 2.71 3.99 4.22 3.88 3.49 3.29 3.62 3.69 4.31 3.43 3.79 3.09 2.90
Johnson & Johnson 1.26 1.33 1.44 1.47 1.72 1.65 1.58 1.41 1.32 1.34 2.52 2.47 2.73 3.08 2.83 2.17 2.51 2.49 2.44
Merck & Co. Inc. 1.26 1.21 1.37 1.17 1.44 1.33 1.42 1.33 1.43 1.50 1.59 1.78 1.89 1.87 1.64 1.55 1.62 1.62 1.61
Pfizer Inc. 0.90 1.47 1.54 1.57 1.43 1.16 1.27 1.35 1.43 1.34 1.44 1.25 1.11 1.37 1.44 1.49 1.62 2.14 2.45
Regeneron Pharmaceuticals Inc. 4.03 3.88 4.58 4.47 4.04 3.62 3.59 3.82 3.63 3.75 2.80 2.56 3.64 3.37 3.41 3.59 3.64 3.80 4.31
Vertex Pharmaceuticals Inc. 3.44 3.74 3.78 3.43 3.71 3.67 3.68 3.28 3.28 3.49 3.82 2.31 2.08 2.33 2.54 2.78 3.63 3.46 4.49
Zoetis Inc. 4.39 4.17 4.05 3.60 4.06 4.38 4.27 3.85 2.80 2.01 1.96 3.03 3.24 3.20 2.84 2.15 2.08 2.11 2.27

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-30), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-07), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-10), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-05-03), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-07-28), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-20), 10-Q (filing date: 2014-10-28), 10-Q (filing date: 2014-07-29), 10-Q (filing date: 2014-04-29).

1 Q3 2019 Calculation
Current ratio = Current assets ÷ Current liabilities
= 14,454 ÷ 5,009 = 2.89

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Celgene Corp.’s current ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level.

Quick Ratio

Celgene Corp., quick ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Cash and cash equivalents 9,604  7,214  5,433  4,234  2,480  1,503  2,819  7,013  5,511  6,660  5,273  6,170  5,523  5,064  4,446  4,880  6,017  4,531  4,368  4,122  3,743  3,220  2,397 
Debt securities available-for-sale 14  613  664  496  66  79  68  3,219  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Equity investments with readily determinable fair values 1,279  1,496  1,594  1,312  1,832  1,828  1,853  1,810  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Marketable securities available-for-sale —  —  —  —  —  —  —  —  6,248  3,480  3,588  1,800  1,346  1,340  1,262  1,672  1,489  2,961  2,946  3,425  3,118  2,994  2,714 
Accounts receivable, net of allowances 2,374  2,451  2,327  2,066  2,120  2,064  1,991  1,921  1,816  1,729  1,614  1,621  1,586  1,515  1,420  1,421  1,272  1,273  1,179  1,167  1,068  1,124  1,073 
Total quick assets 13,271  11,774  10,018  8,108  6,498  5,474  6,731  13,963  13,575  11,869  10,475  9,590  8,455  7,919  7,128  7,973  8,778  8,766  8,493  8,713  7,929  7,337  6,183 
 
Current liabilities 5,009  3,685  3,955  4,057  3,683  4,502  3,115  2,987  4,049  3,240  2,629  2,959  2,649  1,987  1,834  1,969  3,144  2,960  2,097  2,112  1,398  1,492  2,425 
Liquidity Ratio
Quick ratio1 2.65 3.20 2.53 2.00 1.76 1.22 2.16 4.67 3.35 3.66 3.98 3.24 3.19 3.99 3.89 4.05 2.79 2.96 4.05 4.13 5.67 4.92 2.55
Benchmarks
Quick Ratio, Competitors2
Abbott Laboratories 0.93 0.98 0.94 1.03 1.00 0.94 1.04 1.67 2.02 2.13 2.01 3.31 0.94 0.92 0.88 1.04 1.10 1.60 1.45
AbbVie Inc. 0.92 0.64 0.78 0.78 0.95 0.55 0.90 0.89 1.11 0.98 1.24 1.14 1.42 1.41 1.25 1.21 1.57 1.12 1.10
Allergan PLC 0.79 0.61 0.51 0.83 0.65 0.73 0.80 0.95 0.96 1.00 1.11 2.00 3.71 0.34 0.48 0.42 0.52 0.78 0.80
Amgen Inc. 2.28 2.41 2.37 2.44 2.68 2.94 3.42 4.98 5.46 5.47 3.96 3.68 3.90 3.52 4.44 3.97 4.75 4.76 4.68
Biogen Inc. 1.57 1.70 2.07 1.83 2.19 1.79 2.67 1.78 1.62 1.49 1.57 1.94 2.44 2.16 1.91 1.93 2.84 1.57 1.98
Bristol-Myers Squibb Co. 3.63 3.61 1.64 1.39 1.31 1.18 1.29 1.37 1.38 1.36 1.37 1.35 1.24 1.30 1.22 1.07 1.30 1.23 1.44
Eli Lilly & Co. 0.66 0.67 0.65 1.20 1.36 0.96 0.87 0.91 0.94 0.92 0.78 0.98 1.06 1.00 0.98 1.04 1.01 1.01 0.95
Gilead Sciences Inc. 2.74 3.41 3.32 3.15 3.16 2.70 2.60 2.52 3.39 3.01 2.19 1.78 1.57 1.39 1.33 2.07 2.33 1.56 2.17
Illumina Inc. 5.99 5.95 3.28 2.23 2.20 2.39 2.35 3.43 3.65 3.32 2.98 2.75 3.05 3.09 3.63 2.90 3.17 2.59 2.42
Johnson & Johnson 0.93 0.95 1.01 1.08 1.22 1.17 1.08 1.04 0.92 0.91 2.06 2.04 2.25 2.54 2.32 1.77 1.93 1.87 1.80
Merck & Co. Inc. 0.80 0.75 0.88 0.72 0.95 0.82 0.86 0.83 0.97 1.03 1.13 1.24 1.31 1.26 1.13 1.04 1.05 1.02 1.09
Pfizer Inc. 0.50 0.71 0.72 0.84 0.94 0.72 0.76 0.93 0.95 0.88 0.94 0.84 0.70 0.94 0.99 1.07 1.08 1.62 1.81
Regeneron Pharmaceuticals Inc. 3.14 2.99 3.66 3.50 3.10 2.80 2.82 2.98 2.94 3.02 2.34 2.13 3.18 2.94 2.95 3.10 3.18 3.32 3.88
Vertex Pharmaceuticals Inc. 3.20 3.51 3.54 3.19 3.46 3.41 3.39 2.94 2.92 3.06 3.30 2.06 1.81 2.02 2.19 2.41 3.12 2.97 4.17
Zoetis Inc. 2.72 2.58 2.55 2.24 2.31 2.62 2.60 2.34 1.71 0.94 0.92 1.47 1.51 1.49 1.36 1.17 0.98 0.98 1.07

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-30), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-07), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-10), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-05-03), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-07-28), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-20), 10-Q (filing date: 2014-10-28), 10-Q (filing date: 2014-07-29), 10-Q (filing date: 2014-04-29).

1 Q3 2019 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 13,271 ÷ 5,009 = 2.65

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Celgene Corp.’s quick ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level.

Cash Ratio

Celgene Corp., cash ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Cash and cash equivalents 9,604  7,214  5,433  4,234  2,480  1,503  2,819  7,013  5,511  6,660  5,273  6,170  5,523  5,064  4,446  4,880  6,017  4,531  4,368  4,122  3,743  3,220  2,397 
Debt securities available-for-sale 14  613  664  496  66  79  68  3,219  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Equity investments with readily determinable fair values 1,279  1,496  1,594  1,312  1,832  1,828  1,853  1,810  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Marketable securities available-for-sale —  —  —  —  —  —  —  —  6,248  3,480  3,588  1,800  1,346  1,340  1,262  1,672  1,489  2,961  2,946  3,425  3,118  2,994  2,714 
Total cash assets 10,897  9,323  7,691  6,042  4,378  3,410  4,740  12,042  11,759  10,140  8,861  7,970  6,869  6,404  5,707  6,552  7,506  7,492  7,314  7,547  6,861  6,213  5,110 
 
Current liabilities 5,009  3,685  3,955  4,057  3,683  4,502  3,115  2,987  4,049  3,240  2,629  2,959  2,649  1,987  1,834  1,969  3,144  2,960  2,097  2,112  1,398  1,492  2,425 
Liquidity Ratio
Cash ratio1 2.18 2.53 1.94 1.49 1.19 0.76 1.52 4.03 2.90 3.13 3.37 2.69 2.59 3.22 3.11 3.33 2.39 2.53 3.49 3.57 4.91 4.17 2.11
Benchmarks
Cash Ratio, Competitors2
Abbott Laboratories 0.41 0.37 0.36 0.45 0.59 0.36 0.45 1.08 1.41 1.45 1.33 2.82 0.54 0.51 0.47 0.67 0.70 1.22 1.07
AbbVie Inc. 0.61 0.32 0.38 0.47 0.57 0.22 0.56 0.59 0.73 0.59 0.71 0.66 0.87 0.86 0.81 0.77 1.05 0.74 0.72
Allergan PLC 0.47 0.24 0.20 0.33 0.19 0.28 0.35 0.65 0.64 0.67 0.86 1.68 3.41 0.06 0.22 0.13 0.25 0.20 0.28
Amgen Inc. 1.94 2.05 2.07 2.17 2.41 2.62 3.07 4.62 5.05 5.02 3.65 3.40 3.60 3.23 4.08 3.62 4.34 4.35 4.28
Biogen Inc. 1.00 0.92 1.24 1.07 1.39 1.02 1.88 1.10 1.02 0.86 0.96 1.43 1.73 1.51 1.29 1.33 2.22 0.93 1.11
Bristol-Myers Squibb Co. 3.10 3.02 0.99 0.83 0.70 0.62 0.70 0.71 0.75 0.72 0.72 0.72 0.62 0.59 0.57 0.53 0.76 0.74 0.99
Eli Lilly & Co. 0.15 0.20 0.19 0.68 0.83 0.53 0.41 0.55 0.55 0.48 0.34 0.55 0.51 0.47 0.41 0.54 0.52 0.51 0.50
Gilead Sciences Inc. 2.39 3.03 2.97 2.84 2.81 2.38 2.25 2.19 2.96 2.48 1.70 1.29 1.11 0.84 0.76 1.48 1.68 0.96 1.52
Illumina Inc. 5.11 5.18 2.91 1.95 1.95 2.06 2.01 2.88 3.07 2.78 2.47 2.21 2.44 2.45 2.79 2.27 2.47 2.08 1.92
Johnson & Johnson 0.51 0.49 0.53 0.63 0.71 0.66 0.56 0.60 0.51 0.45 1.57 1.59 1.74 1.98 1.80 1.38 1.48 1.39 1.31
Merck & Co. Inc. 0.39 0.35 0.47 0.40 0.55 0.42 0.43 0.46 0.58 0.64 0.77 0.83 0.84 0.79 0.74 0.70 0.69 0.65 0.76
Pfizer Inc. 0.25 0.40 0.39 0.59 0.59 0.42 0.42 0.66 0.60 0.53 0.59 0.57 0.41 0.65 0.68 0.79 0.74 1.25 1.37
Regeneron Pharmaceuticals Inc. 1.63 1.56 2.14 1.95 1.55 1.26 1.28 1.24 1.21 1.23 1.00 0.84 1.47 1.10 0.92 1.29 1.22 1.00 1.38
Vertex Pharmaceuticals Inc. 2.88 3.14 3.14 2.83 3.08 2.98 2.99 2.59 2.55 2.67 2.88 1.81 1.56 1.72 1.86 2.06 2.68 2.72 3.91
Zoetis Inc. 1.74 1.66 1.66 1.39 1.39 1.61 1.65 1.43 1.13 0.40 0.36 0.65 0.63 0.63 0.58 0.65 0.36 0.35 0.41

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-30), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-07), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-10), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-05-03), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-07-28), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-20), 10-Q (filing date: 2014-10-28), 10-Q (filing date: 2014-07-29), 10-Q (filing date: 2014-04-29).

1 Q3 2019 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 10,897 ÷ 5,009 = 2.18

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Celgene Corp.’s cash ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level.